Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Ultra Short Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VUSB | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $812.27 | $50.03 |
52-Week Low | $545.46 | $49.60 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VUSB trades at $49.70, showing minimal daily movement with a slight 0.02% gain. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Recent dividend payments of $0.17-$0.18 per share indicate ongoing shareholder returns. Financial media highlights potential benefits from Federal Reserve policy shifts favoring short-term bonds.
The outlook remains cautiously optimistic given the ETF's focus on short-term bonds amid potential rate hikes. Key risks include interest rate sensitivity and market volatility. Analyst sentiment appears balanced, with technical indicators suggesting near-term consolidation around current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
